Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Burosumab→

Burosumab Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1610833-03-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Fully human monoclonal antibodyfibroblast growth factor 23 (FGF23) inhibitor
Mechanism of action
Binds FGF23 and inhibits its biological activity, restoring renal tubular phosphate reabsorption and increasing renal production of 1,25-dihydroxyvitamin D. This increases serum phosphate availability for bone mineralisation.
Indications / reported uses
  • Treatment of X-linked hypophosphataemia (XLH) in eligible adults and children aged 6 months and older, according to product-specific age and clinical criteria
  • Treatment of tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised, in eligible adults and paediatric patients aged 2 years and older under the applicable US label

Sources: US FDA prescribing information — CRYSVITA, updated 2026 · EMA EPAR — Crysvita · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Fully human monoclonal antibody; fibroblast growth factor 23 (FGF23) inhibitor

Mechanism of action

Binds FGF23 and inhibits its biological activity, restoring renal tubular phosphate reabsorption and increasing renal production of 1,25-dihydroxyvitamin D. This increases serum phosphate availability for bone mineralisation.

General use cases

  • Treatment of X-linked hypophosphataemia (XLH) in eligible adults and children aged 6 months and older, according to product-specific age and clinical criteria
  • Treatment of tumour-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised, in eligible adults and paediatric patients aged 2 years and older under the applicable US label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Burosumab Environmental Risk Assessment (ERA) (the Burosumab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.